APPLIED PHARMACEUTICAL TOXICOLOGY 2020
Save the Date!
May 12 - 14, 2020
Takeda, 35 Landsdowne Street, Cambridge, MA
Plenary Speakers for 2020
 |
Jeffrey Gotts, MD, PhD Assistant Professor, Department of Medicine, UCSF e cigarettes - title TBA |
|
 |
Kristen Hege, MD Vice President, Translational Development, Hematology/Oncology, Celgene Title TBA |
|
 |
Lisa Plitnick, PhD Senior Research Scientist, Merck Discovery and Development of Vaccines and Worldwide Regulatory Experience |
|
Speakers Confirmed for 2020
 |
Brian Enright, PhD, DABT Senior Principal Scientist, Preclinical Safety, AbbVie Utility of Juvenile Animal Studies for Antibody-Drug Conjugates |
|
Juliane Gust, MD, PhD Center for Integrative Brain Research, Seattle Children's Hospital CAR T Neurotoxicity: Translational Insights |
|
| |
||||
 |
Tracy Henriques, PhD, DABT Toxicologist, AbbVie Preclinical to Clinical Translation of ADA: Putting Data to the Dogma |
|
Hervé Lebrec, PharmD, PhD, DABT Scientific Director, Translational Safety & Bioanalytical Services, Amgen Experience with Nonhuman Primate Models in CAR-T Therapy Nonclinical Safety Assessment |
|
| |
||||
 |
Lisa Mangus, DVM, PhD, DACVP Assistant Professor, Dept. of Molecular & Comparative Pathobiology, Johns Hopkins School of Medicine Title TBA |
|
Kim Maratea, DVM, PhD, DACVP Associate Director Pathology, Oncology Safety, AstraZeneca Early Assessment of Bone Marrow Toxicity in Immunodeficient Mice |
|
| |
||||
 |
John McNulty, PhD Director, Shire/Takeda Nonclinical Safety Considerations in the Development of Treatments for Rare Diseases at Shire |
|
Suman Mukherjee, PhD Director, In Vivo PK and TK Group, Safety Assessment, Merck The Impact of Toxicokinetics on the Design and Interpretation of Toxicology Studies |
|
| |
||||
 |
Daniel Nomura, PhD Professor of Chemical Biology, University of California at Berkeley Reimagining Druggability using Chemoproteomic Platforms
|
|
Kara Pearson, PhD Director, Analytical and Biochemical Toxicology, Merck Using Stable Isotope Labeled Tracers to Illuminate Aspects of Hepatic Function and Provide a Translational Biomarker of BSEP Inhibition |
|
| |
||||
 |
Michael Polydefkis, MD MHS Professor, Neurology, Johns Hopkins University School of Medicine TBA |
|
Nicola Stagg, PhD, DABT Senior Scientist/Toxicologist, Genentech Title TBA
|
|
| |
||||
 |
Jonathan Stauber, PhD Director, ImaBiotech Role of Drug Exposure Quantification for Safety and Efficacy Evaluation in Non Clinical and Clinical Trials |
|
Jessica E. Sutherland, PhD, DABT Senior Director, Toxicology, Alnylam Pharmaceuticals Title TBA |
|
| |
||||
|
|
Francis Wolenski, PhD, DABT Senior Toxicologist, Drug Safety Research & Evaluation, Takeda Navigating a Tough Regulatory Interaction – Is this Phase 1 or 2? |
Additional Speakers Confirmed for 2020
Rogely Boyce, Consultant, Beechy Ridge ToxPath, LLC
Christopher Brynczka, Senior Principal Scientist, Merck
Paola Costaldi, Associate Director, Head of Chemical Biology, AstraZeneca
Lucas Kempf, Medical Officer Rare Diseases Program, FDA
Scott Mittelstadt, Director, Investigative Toxicology and Safety Pharmacology, AbbVie
Mohan Rao, Computational Toxicologist/Biologist, AbbVie
Chandra Saravanan, Senior Veterinary Pathologist, Novartis Institutes for BioMedical Research
Larry Whiteley, Sr. Director, Pfizer
Sessions for the 2020 Discovery Toxicology Workshop
Session I: IO in Discovery Toxicology Space
Session II: Novel Approaches to Identify Off-Target Drivers of Toxicity
Session III: Case Studies in Investigative Toxicology
Sessions for the 2020 Development Toxicology Workshop
Session IV: Regulatory Hurdles
Session V: Developing Products for Rare Diseases and Conditions
Session VI: Non-Clinical to Clinical Translation - Case Studies
Session VII: Peripheral Neuropathy
Download APT 2019 Program Guide
Join our LinkedIn Group